Abstract 1963P
Background
Chordoma is a rare type of bone cancer with limited treatment options. Encouraging results showing the efficacy of pembrolizumab, a PD1 checkpoint inhibitor, in chordomas have recently been reported. Here, we performed comprehensive molecular testing to dissect the immune profile of these tumors and elucidate mechanisms of therapy response in chordomas.
Methods
Whole exome sequencing (WES) and whole transcriptome analysis was performed on samples from 14 patients (n = 6 samples from skull base, n = 8 samples from spine) with chordoma. Retrospective analysis of BostonGene’s Tumor Portrait® test results identified genomic and transcriptomic alterations of chordomas and classified tumor microenvironment (TME) subtypes according to methods from Bagaev, et al., 2021.
Results
The median age of patients was 54.5 years (range: 26-76 years). The histologic subtypes were conventional (n = 13) and dedifferentiated (n = 1). The median number of prior therapies was 1 (range: 0-3). Transcriptomic-based TME classification revealed 93% (n = 13) of patients had an immune-enriched (IE) TME subtype characterized by high levels of B cells and CD4+ T cells and low levels of tumor-associated macrophages. Only one patient had a fibrotic TME characterized by minimal immune infiltration and a high prevalence of stromal elements. High CD274 (PD-L1) expression was observed in 57% of samples. EGFR expression was high in all samples. In three cases, a 22q deletion was identified. Other clinically actionable events included SMARCB1 loss (n = 3), TP53 alteration (n = 2), BRCA1 loss (n = 1), a combination of PTEN, NF2, and TRAF2 loss (n = 1), and CDKN2A/B loss (n = 1). All samples were microsatellite stable and had low tumor mutational burden (range: 0.31-1.32 mut/Mb). From this cohort, 50% of patients were matched with at least one clinical trial based on their molecular profiles.
Conclusions
The prevalence of IE TME subtypes in chordomas supports the previously reported response to immune checkpoint inhibitors in chordomas. Together, these findings indicate next-generation sequencing could be a useful tool for informing treatment selection in advanced chordomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BostonGene, Corp.
Funding
BostonGene, Corp.
Disclosure
M. Voropaeva, I. Zhuk, A. Aukhadieva, K. Zirov, A. Makarova, L. Bednyagin: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Bagaev: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp.
Resources from the same session
1982P - Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Presenter: Jihua Yang
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15